Sacituzumab govitecan
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Sacituzumab govitecan
Apr 28, 2024, 19:14 |
Insight
Andrea Necchi: Pleased to see the interim results of SURE01 trial slated for presentation at ASCO24
Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on LinkedIn: "Very pleased to…
Apr 27, 2024, 14:44 |
Insight
Aruni Ghose: Our review delves into the progress across urological malignancies and discusses future directions in ADC development
Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust, shared a post on LinkedIn:…
Apr 22, 2024, 19:23 |
Insight
New Paper Alert! A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners Foundation
A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners…
Apr 2, 2024, 05:10 |
Blog
Chul Kim: March has been fruitful and rewarding, as we launched two IITs of ADC back to back!
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared on X/Twitter: "March has been fruitful…
Jan 24, 2024, 22:30 |
Insight
Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
Raffaele Colombo, Principal Scientist at Zymeworks, shared on X: "Evoke-01 study of sacituzumab govitecan (SG)…
Jan 7, 2024, 15:14 |
Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Dec 15, 2023, 05:57 |
Blog
Paolo Tarantino: In our recent Nature Review we suggested some strategies to mitigate toxicity of novel ADC
Paolo Tarantino, clinical research fellow at the Dana-Farber Cancer Institute, shared a post on X/Twitter:…
All:
7
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube